Clinical Trial: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum

Brief Summary: The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

Detailed Summary:
Sponsor: XOMA (US) LLC

Current Primary Outcome: Improvement in the Investigator's Assessment of the pyoderma gangrenosum target ulcer [ Time Frame: Day 1 through Day 84 ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: XOMA (US) LLC

Dates:
Date Received: June 17, 2013
Date Started: May 2013
Date Completion:
Last Updated: February 2, 2016
Last Verified: February 2016